All the Active Ingredient Drugs
SNRI. Venlafaxine (HCl) 75 mg, 150 mg. E.R CAPS.: 28. Major depress. Episodes: The recomm. starting dose for prolong. release venlafaxine is 75 mg×1/d. Pts. not respond. to the init. 75 mg/d dose may benefit from dose incr. up to a max. dose of 375 mg/d. Dosage incr. can be made at interv. of 2 wks. or more. If clinic. warranted due to sympt. sever., dose incr. can be made at more freq. interv., but not less than 4 d. Contin. for at least 6 mnths. follow. remiss.
GAD: The recomm. starting dose for prolong. rel. venlafaxine is 75mg×1/d. Pts. not respond. to the init. 75 mg/d dose may benefit from dose incr. up to a max. dose of 225 mg/d. Dosage incr. can be made at interv. of 2 wks. or more.
SAD: The recomm. dose for prolong. rel. venlafaxine is 75mg×1/d. There is no evidence that higher doses confer any addit. benefit.
However, in individ. pts. not respond. to the init. 75 mg×1/d, incr. up to a max. dose of 225 mg/d may be consid. Dosage incr. can be made at interv. of 2 wks. or more.
For the tmt. of depress. Mainten. of recur. depress. Generalized anxiety Disord. (GAD) - short term & long-term. Social anxiety Disord. (SAD).
C/I: Hypersens. Concom. tmt. with irrevers. MAOIs. Venlafaxine must not be initiat. for at least 14 d after discont. of tmt. with an irrevers. MAOI. Venlafaxine must be discont. for at least 7 d before starting tmt. with an irrevers. MAOI.
SNRI. Venlafaxine (as HCl) 37.5 mg, 75 mg. TABS: 28. 2 tabs dly.
Depression.
C/I: Hypersens., pregn., lact., concur. use
MAOI’s. See lit.
SNRI. Venlafaxine (as HCl) 37.5, 75 mg. Tabs 28 X 37.5 / 75 mg
Initial: 75 mg/day in 2 divided doses; non responders: may incr. up to 375mg/day at intervals of not less than 2 weeks. If clinically warranted due to symptoms severity, dose may be increased at more frequent intervals but not less than 4 days. See Lit. Hepatic/renal impair.;elderly/ children and adolescents; maint. tmt./discontinuation : See lit.
Treatment of depression.
C/I: Hypersens. Conc. tmt with irreversible MAOIs. Must not be init. for at least 14 days after discont. of tmt. with an irrev. MAOI. Must be discont. for at least 7 days before starting tmt. with irrev. MAOI.
See lit.
SNRI. Venlafaxine (HCl) 75, 150, 225 mg. CAPS: 30x75 mg. TABS: 30x150 mg, 225 mg.
Initial: 75 mg 1 × dly; Patients not responding to the initial 75 mg/day dose:
Depression: may incr. up to 375 mg dly at intervals of not less than 2 weeks. If clinically warranted due to symptoms severity, dose may be increased at more frequent intervals but not less than 4 days. See Lit.
GAD, SAD: Incr. up to 225 mg dly at intervals not less than 2 weeks: See Lit
Hepat./ren. impair./elderly/ children and adolescents: See lit.
Discont: grad. reduced, monitor pt. See lit.
Treatment of depression; Maintenance of recurrent depression, generalized anxiety disorder (GAD) - short term and long term, social anxiety disorder (SAD).
C/I: Hypersensitivity to the active substance or to any of the excipients. Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible MAOI. See lit.
